Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1995-06-07
2000-03-07
Achutamurthy, Ponnathapura
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
435 697, 53038835, C07K 1600, C12P 2104
Patent
active
060342234
ABSTRACT:
This invention provides an immunoconjugate which comprises 1) a non-peptidyl toxin and 2) a CD4-gamma2 chimeric heavy chain homodimer linked thereto. This invention also provides an immunoconjugate which comprises 1) a gamma radiation-emitting radionuclide of low to moderate cytotoxicity and 2) a CD4-gamma2 chimeric heavy chain homodimer linked thereto. This invention further provides an immunoconjugate which comprises 1) a non-peptidyl toxin and 2) a heterotetramer comprising two heavy chains and two light chains, both heavy chains being either a) IgG2 heavy chains or b) chimeric CD4-IgG2 heavy chains, and both light chains being either a) kappa light chains or b) chimeric CD4-kappa light chains. This invention further provides an immunoconjugate which comprises 1) a gamma radiation- emitting radionuclide of low to moderate cytotoxicity and 2) a heterotetramer comprising two heavy chains and two light chains, both heavy chains being either a) IgG2 heavy chains or b) chimeric CD4-IgG2 heavy chains, and both light chains being either a) kappa light chains or b) chimeric CD4 kappa light chains. Finally, this invention provides methods of using the immunoconjugates of the subject invention.
REFERENCES:
Fahey et al., Status of immune-based therapies in HIV infection and AIDS Clin. Exp. Immunol. (1992) 88, 1-5 Jan. 1992.
Fox, J.L., No winners against AIDS, Bio/Technology, (1994) vol. 12, Feb. p. 128 1994.
Ashorn, P., et al.,Elimination Of Infectious Human Immunodeficiency Virus From Human T-Cell Cultures By Synergistic Action Of CD4-Pseudomonas Exotoxin And Reverse Transcriptase Inhibitors, Proc. Nat'l. Acad. Sci. USA 87:8889-8893 (1990).
Aullo, P., et al., A Recombinant Diptheria Toxin Related Human CD4 Fusion Protein Specifically Kills HIV Infected Cells Which Express gp120 But Selects Fusion Toxin Resistant Cells Which Carry HIV, EMBO Journal 11, No. 11(2):575-583 (1992).
Byrn, R.A., et al., Biological Properties Of A CD4 Immunoadhesin, Nature 344:667-670 (1990).
Capon, D.J., et al., Designing CD4 Immunoadhesins for AIDS Therapy, Nature 337:525-531 (1989) (Exhibit B).
Chaudhary, V.K., et al., Selective Killing Of HIV-Infected Cells By Recombinant Human CD4-Pseudomonas Exotoxin Hybrid Protein, Nature 335:369-372 (1988).
Gartner, S. et al., The Role of Mononuclear Phagocytes in HTLV-III/LAV Infection, Science 233:215-219 (1986) (Exhibit C).
Houghton, A.N. and Scheinberg, D.A., Monoclonal Antibodies: Potential Applications to the Treatment of Cancer, Seminars in Oncology, 13(2):165-178 (1986) (Exhibit D).
Jarman, M., A Radical Approach To Cancer, Nature 349:566-567 (1991).
Lasky, L.A., et al., Delineation Of A Region Of The Human Immunodeficiency Virus Type 1 gp120 Glycoprotein Critical For Interaction With The CD4 Receptor, Cell 50:975-985 (1987).
Moore, J.P., et al., Dissociation of gp120 From HIV-1 Virions Induced By Soluble CD4, Science 250:1139-1142 (1990).
Morrison, S.L., et al., Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains With Human Constant Region Domains, Proc. Natl. Acad. Sci. USA 81:6851-6855 (1984).
Nicolaou, K.C., et al., Designed Enediynes: A New Class Of DNA-Cleaving Molecules With Potent And Selective Anticancer Activity, Science 256:1172-1178 (1992).
Pound, J.D. and Walker M.R., Membrane Fc Receptors For IgG Subclasses, in The Human IgG Subclasses: Molecular Analysis Of Structure, Function and Regulation, Pergamon Press, Oxford, U.K. 111-133 (1990).
Schooley, R.T., et al., Recombinant Soluble CD4 Therapy In Patients With The Acquired Immunodeficiency Syndrome (AIDS) And AIDS-Related Complex, Ann. Internal Med. 112:247-253 (1990).
Till, M.A., et al., HIV-Infected Cells Are Killed By rCD4-Ricin A Chain, Science 242:1166-1168 (1988).
Traunecker, A., et al., Highly Efficient Neutralization Of HIV With Recombinant CD4-Immunoglobulin Molecules, Nature 339:68-70 (1989).
Magerstadt, M., et al., Antibody Conjugates and Malignant Disease, CRC Press, Boca Raton, FL. (1991).
Allaway Graham P.
Maddon Paul J.
Achutamurthy Ponnathapura
Park Hankyel T.
Progenics Pharmaceuticals Inc.
White John P.
LandOfFree
Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunocon does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunocon, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunocon will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-364371